Swiss industrial firms Clariant and Lonza have both posted weaker than expected first half profits, in part due to the strength of the Swiss franc.
This content was published on
1 minute
swissinfo.ch and agencies
Basel-based specialty chemicals company Clariant on Wednesday posted a rise in net profit to SFr40 million ($49.80 million), but this was lower than had been forecast.
Clariant warned in its statement that raw material prices would rise in the second half after a sharp increase in the second quarter.
The chemicals maker Lonza Group, also headquartered in Basel, reported a 28.1 per cent drop in first-half net profit due to the franc, but said that revamp efforts, its recent acquisition of United States peer Arch Chemicals and healthy industry demand should allow it to reach its full-year targets.
Lonza’s net profit for the first six months of the year fell to SFr97 million from SFr135 million a year earlier.
The strong franc caused sales to fall 8.3 per cent to SFr1.19 billion from SFr1.30 billion. Lonza Chief Executive Stefan Borgas said that without the currency hit underlying growth was solid, and he was confident for the months ahead.
To reduce its dependence on Switzerland, where Lonza incurs a substantial part of its costs, the company has agreed to buy US biocides maker Arch Chemicals for $1.2 billion.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Strong franc may cause longer work hours
This content was published on
Swiss firms are searching for creative solutions to deal with a strong franc which has gained 25 per cent in value against the euro and the dollar over the past four years. Lonza, the Basel-based chemical and biotechnology company, which on Monday agreed to buy Arch Chemicals in the United States for $1.2 billion (SFr1…
This content was published on
Profit rose to SFr222 million ($178 million) from SFr188 million in 2005, while turnover was up by 15.6 per cent to SFr2.91 billion. Lonza said it expected sales growth of eight to 12 per cent over the next few years and operating profit growth in the mid to high teens. The company has repositioned itself…
This content was published on
But while global competitors have experienced the same difficulties, the Basel-based duo have also been stung by the strong Swiss franc and strategic problems, according to analysts. Both companies operate in a competitive market producing chemicals, such as dyes and pigments, for the car, plastics, paper, construction and textile industries. Ciba shares plummeted on Tuesday…
This content was published on
The sector’s lobby group said customs duties, red tape and patent abuses are draining funds away from vital research. But it insists a price-inflating ban on parallel imports should stay in place. A study commissioned by the Association of the Swiss Chemical and Pharmaceutical Companies showed the sector dominating the Swiss export market. Pharmaceutical and…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.